Kornimate/medical-research-clean huggingface dataset:
exercise and pain sensitivity in knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: a commonly administered conservative non-pharmacological treatment for oa is exercise, with beneficial effects in terms of reduced pain and disability. while the link between exercise and reduced disability is mediated by e.g. increased muscle strength and endurance, the analgesic mechanisms related to exercise are unexplored. knee oa patients have both peripheral and central sensitization of pain mechanisms resulting in hyperalgesia. thus, targeted pain treatment in these patients may focus on both peripheral and central mechanisms but it unknown if exercise affects either of these mechanisms. it is hypothesized that in knee oa patients exercise reduces the pain sensitivity


Eligibility criteria:
inclusion criteria: * age above 40 years * clinical diagnosis of tibiofemoral osteoarthritis * radiographic verification of diagnosis (kellgren\&lawrence 2 or 3) * ability to participate in examinations * ability to participate in exercise sessions * 20≤ body mass index (bmi) ≤35 kg/m2 * ability to comply with rules about concomitant medication and therapy * speak, read and write danish exclusion criteria: * participation in exercise training for the knee osteoarthritis within 3 months of enrollment * counterindications for exercise * pregnant or breastfeeding * current or previous autoimmune disease * history of surgical joint replacement in the lower limbs * planned surgery * current or previous diagnosis or signs of cardiovascular disease * neurological disorders * alcohol or drug abuse * diabetes * psychiatric disorders * regional pain syndromes * regional pain caused by lumbar or cervical nerve root compression * counterindications to mr scan * counterindications to mr contrast
incheon-bucheon cohort of patients undergoing primary pci for acute stemi

Conditions: Myocardial Infarction

Summary: incheon-bucheon cohort of patients undergoing primary percutaneous coronary intervention for acute st-elevation myocardial infarction (interstellar) registry is a retrospective, observational, 4-regional-hospital based registry reflecting current practices of management, risk factors, and clinical outcomes in patients with st-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention at cities of incheon and bucheon located in the mid-western part of the korean peninsula between 2007 and 2014.

incheon-bucheon cohort of patients undergoing primary percutaneous coronary intervention for acute st-elevation myocardial infarction (interstellar) registry is a retrospective, observational, 4-regional-hospital based registry reflecting current practices of management, risk factors, and clinical outcomes in patients with st-segment elevation myocardial infarction (stemi) undergoing primary percutaneous coronary intervention (pci) at cities of incheon and bucheon located in the mid-western part of the korean peninsula between 2007 and 2014. diagnosis of acute stemi was based on clinical data findings including typical symptoms, 12-lead electrocardiography, and blood test. decisions regarding primary pci were made by at least 2 attending cardiologists at the time of presentation. demographic data, cardiovascular risk factors, laboratory data and clinical follow-up data were collected. baseline blood test was obtained and recorded as part of the routine care for patients who visited the emergency room for chest pain and in whom acute coronary syndrome was suspected. standard medical management was provided by responsible physicians.

Eligibility criteria:
inclusion criteria: * patients diagnosed with acute st-segment elevation myocardial infarction * patients treated with primary percutaneous coronary intervention exclusion criteria: * patients diagnosed with non-st-segment elevation acute coronary syndrome * patients treated with thrombolytic therapy

Keywords: st-segment elevation myocardial infarction primary percutaneous coronary intervention clinical outcomes
tdcs in the prevention of relapse after electroconvulsive therapy

Conditions: Depression

Summary: while electroconvulsive therapy (ect) in major depression is effective, high relapse rates and cognitive side effects limit its long-term use. there is no consensus about optimal continuation pharmacological treatments after a ect course. adjunction of tdcs to pharmacological continuation treatment after ect may decrease relapse rates.

in a prospective, randomized, double blind, controlled, long-term study, investigators assign 40 depressed patients, in remission after ect course associated to venlafaxine, with lithium adjunction after ect course, either to tdcs or sham tdcs. depressive symptoms and cognition were assessed after acute ect after six months of continuation therapy.

Eligibility criteria:
inclusion criteria: * 18-75 ans * remission (madrs \<10) of a major depressive episode after acute treatment with ect + venlafaxine * lithium adjunction 48h after the last ect session * no comorbid psychiatric disorder, excluding personality disorder or nicotine dependance. * capacity to consent * sufficient comprehension of the french language exclusion criteria: * contra-indications to tdcs * neurologic conditions * severe medical conditions. * pregnancy/breast-feeding. * current use of benzodiazepines or antipsychotics

Keywords: depression moods disorders electroconvulsive therapy
visual outcome and visual quality after bilateral implantation of the acrysof® iq iol compared to mi60® and tecnis® iol

Conditions: Cataract

Summary: the objective of the study is to compare the visual outcomes of three aspheric monofocal intraocular lenses after cataract surgery - acrysof® iq, tecnis® and akreos® mi60.


Eligibility criteria:
inclusion criteria: * male or female subjects, aged 50 and over. * subjects diagnosed with bilateral cataracts requiring cataract extraction and implantation of a posterior chamber intraocular lens. * subjects must be willing to undertake the additional ophthalmic tests within 3 months of the second lens implantation. * subjects must be assessed to be able to dilate to a minimum of 6 mm pre operatively. * subjects' pupil size must be ≥ 4.5 mm in mesopic conditions. exclusion criteria: * subjects who have previously had corneal surgery. * subjects who have potential visual acuity which is \< 6/12 due to other ocular pathology * subjects with corneal pathology. * subjects with astigmatism of greater than 1d. * subjects diagnosed with glaucoma. * subjects diagnosed with diabetes. * subjects who have previously participated in a clinical investigation within 30 days prior to enrolment * subjects with a know history of poor compliance * subjects with planned adjunctive surgery

Keywords: cataract, intraocular lens
effect of ready to use therapeutic food (rutf) supplement after an episode of malaria falciparum on weight

Conditions: Weight Loss; Weight Gain; Convalescence; Malaria

Summary: the primary objective of this study is to determine to what extent provision with rutf will promote catch up growth in children following an acute uncomplicated episode of p. falciparum malaria.

anorexia due to infection might lead to weight loss. in many settings total recovery is problematic what might result in a permanent lower weight. a short period high quality food supplementation could improve weight gain after an infection. children aged 6-59 months presenting with malaria caused by p. falciparum who are provided with a rutf supplement (plumpynut®) of 500 kcal/day for 2 weeks will show significantly better catch up growth compared to a similar patient group not provided with rutf (at 2 weeks and 4 weeks post-intervention).

Eligibility criteria:
inclusion criteria: * age 6 to 59 months, and * positive rapid diagnostic test (paracheck®) and * thick smear showing infection with p. falciparum and * informed consent from parents or guardian aged at least 18 years. exclusion criteria: * children who are exclusively breast fed or * children who are severely malnourished (muac \<110 mm and/or bilateral oedema, or who weight-for-height criteria \<3 z-scores) or * presence of general danger signs or signs of severe malaria as defined by the who criteria, or * known history of allergy to malaria drugs, or * having a sibling enrolled in the study.

Keywords: weight loss weight gain malnutrition convalescence malaria rutf ruf supplementation nutrition
fed-fasted, single and multiple ascending dose trial of xen-d0103

Conditions: Atrial Fibrillation

Summary: this study is an evaluation of the safety and tolerability of xen-d0103 in healthy subjects. part 1 assesses the safety, tolerability and blood levels of the ascending single doses of xen-d0103. blood levels of xen-d0103 will be assessed when administered with food and also without food in part 2. the safety, tolerability and blood levels of xen-d0103 will be assessed following dosing for 10 days in part 3.


Eligibility criteria:
inclusion criteria: * for parts 1 and 3 healthy, male subjects aged 18 to 45 years, inclusive. for part 2 healthy, male and female subjects aged 45 to 65 years, inclusive. * females must be of non-childbearing potential exclusion criteria: * subject has a known heart disease. * subject has any of qtcf \> 450 msec, pr ≥ 210 msec or qrs ≥ 120 msec at screening (determined from median of three readings). * for part 1 only: subject has resting heart rate outside of the range 45 to 80 beats per minute (bpm) at screening (determined from median of three readings). * subject has any other condition which, in the investigator's opinion will interfere with the trial. * subject has a systolic blood pressure (bp) \ 160 mmhg at screening or a diastolic bp \>90 or \<45 mmhg at screening. * subject has a clinically significant abnormal laboratory test result at screening. * female subject who is pregnant or breast feeding and female subjects of childbearing potential.
a multicenter clinical trial for the treatment of children and adolescents with soft tissue sarcoma stage 4

Conditions: Sarcoma, Soft Tissue

Summary: phase ii study to evaluate the response on two blocks of topotecan and carboplatin

phase ii study for patients with chemosensible soft tissue sarcoma stage iv in children and adolescents ; response according to recist criteria following two blocks of combination therapy consisting of topotecan and carboplatin

Eligibility criteria:
inclusion criteria: * soft tissue sarcoma chemosensible, stage iv * age \< 21 * measurable tumor lesions exclusion criteria: * lack of cooperation by the patient * no willingness of follow-up examinations * participation on another clinical trial at the same time * death due to the sickness within four weeks

Keywords: sarcoma, soft tissue
clinical trial assessing the herv-w env antagonist gnbac1 for efficacy in ms

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the humanised igg4 monoclonal antibody gnbac1 targets the envelope protein (env) of the human endogenous multiple sclerosis-associated retrovirus (herv-w msrv), which may play a critical role in multiple sclerosis (ms). this study evaluates the effect on mri lesions parameters, the safety and pharmacokinetics of gnbac1 in patients with relapsing remitting multiple sclerosis.


Eligibility criteria:
main inclusion criteria: * for male or female with reproductive potential, use of reliable means of contraception; * rrms according to the 2010 revised mcdonald criteria; * disease activity characterised by at least one documented relapse within the last 12 months and /or at least one gd-enhancing t1 lesion at selection or evidenced within the last 3 months; * edss score \< 6.0. main exclusion criteria: * patients suffering from secondary progressive ms and primary progressive ms at screening; * pregnant and nursing women.

Keywords: multiple sclerosis multiple sclerosis relapsing-remitting gnbac1 mri monoclonal antibody multiple sclerosis associated retrovirus msrv ms rrms herv-w temelimab
has pulmonary rehabilitation a positive impact on sleep quality in patients suffering from copd ?

Conditions: COPD

Summary: the purpose of our study is to assess the impact of pulmonary rehabilitation on objective sleep quality in copd patients.

copd patients suffer from bad sleep quality. about 27 -50% are suffering from insomnia, and respiratory related symptoms are also inducing sleep disturbances. recently, a correlation between altered sleep quality and low activity levels have been shown in this population. in primary insomnia, it is well established that physical activity has a positive impact on sleep quality. the purpose of our study is to assess the impact of pulmonary rehabilitation on objective sleep quality in copd patients.

Eligibility criteria:
inclusion criteria: * copd patients * able to walk and cycle exclusion criteria: * shift work * orthopedic diseases of limbs

Keywords: copd pulmonary rehabilitation insomnia sleep quality physical activity
evaluating the physiological strain induced by a bc protective undergarment under exercise-heat stress

Conditions: Physiological Stress

Summary: israel ministry of defense is examining a new protective undergarment of gore company (chempark fabric) for the police forces. the goal of this research is to perform a comparative experiment in order to evaluate the physiological strain induced by a bc protective undergarment under exercise-heat stress conditions.

in order to physiologically evaluate a new bc protective garment for the israeli police use under exercise-heat stress conditions, 10 young and healthy civilian volunteers will participate in this study. the subjects will undergo 5 experiment days: recruitment day, one day of acclimatization to heat, and 3 days of performing experiment protocol, each day dressed with different protective garment (protective garment in current use + nbc mask, new bc protective undergarment + standard combat uniforms, new bc protective undergarment + standard combat uniforms + nbc mask). core (rectal) and skin temperature and heart rate will be monitored continuously, liquid balance will be recorded.the physiological heat strain will be assessed and compared between the different protective garments.

Eligibility criteria:
inclusion criteria: * aged 18-40 years. * healthy civilian volunteers. * without known medical illness or medication use. exclusion criteria: * the existence or suspicion of existing cardiac or respiratory disease. * hypertension. * diabetes. * psychiatric condition. * any muscles or skeleton condition. * any hormonal disease or any other chronic illness that may inhibit participation in the experiment. * infectious disease 3 days prior to the experiment.
panorama - real world molecular testing, treatment patterns, and clinical outcomes egfr mutation-positive nsclc

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: the objectives of this study are to assess molecular testing, treatment patterns, and associated outcomes among patients with egfr (epidermal growth factor receptor) mutation-positive locally advanced or advanced nsclc (non-small cell lung cancer) who have progressed on or after egfr-tki (egfr-tyrosine kinase inhibitor) therapy post availability of a third-generation tki (primary study cohort). additionally, molecular testing and treatment patterns will be assessed among a secondary cohort of patients which will include patients diagnosed with de-novo egfr t790m mutation-positive locally advanced or advanced nsclc.


Eligibility criteria:
inclusion criteria - primary study cohort * provision of written informed consent (patient consent should be within 6 weeks of disease progression, defined elsewhere as the index date) * adult male or female subjects (according to age of majority/adulthood as defined by local regulations) * patients with prior confirmed egfr mutation-positive (all mutations) locally advanced or advanced nsclc - patients who developed resistance to an egfr-tki due to any other phenotypic/histologic transformations (e.g., small-cell lung cancer, emt) or other mutations (e.g., her2, met amplifications) at the index-date will be eligible for participation in this study as long as they have prior confirmed diagnosis of egfr mutation-positive (all mutations) locally advanced or advanced nsclc * patients who have progressed on or after egfr-tki therapy (i.e., gefitinib, erlotinib or afatinib) within the patient selection period inclusion criteria - secondary study cohort * provision of written informed consent (patient consent should be within 6 weeks of nsclc diagnosis, defined elsewhere as the index date) * adult male or female subjects (according to age of majority/adulthood as defined by local regulations) * patients diagnosed with de-novo egfr t790m mutation-positive locally advanced or advanced nsclc during the patient selection period. the de-novo t790m mutation can be alone or in combination with other mutations (e.g., l858r and t790m). exclusion criteria - primary and secondary study cohorts • enrollment in studies that prohibit any participation in this non-interventional study. these patients will be censored.

Keywords: epidermal growth factor receptor (egfr), non-small cell lung cancer (nsclc), egfr t790m, egfr mutation-positive locally advanced or advanced nsclc
development of a non-invasive screening tool to predict metabolic dysfunction-associated steatotic liver disease

Conditions: Healthy; Fatty Liver; MASLD; MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease; Obesity and Obesity-related Medical Conditions

Summary: a generic screening study to establish structural and/or functional baselines of specific organs.

fatty liver disease is a common condition (25% of the population) which can lead to liver inflammation, liver scarring and even liver cancer. clinical trials are often performed in healthy volunteers, who may have underlying fatty liver without knowledge of it. in clinical trials fatty liver can both mean volunteers have abnormal liver tests, preventing them joining the trial, as well as more likely to have a possible liver drug reaction, causing volunteers to withdraw from a clinical trial of a new drug. the principal objective of the study is to develop a clinical scoring tool that can accurately predict fatty liver disease in study volunteers, without the need for invasive tests (such as a tissue biopsy). we aim to recruit initially 2000 volunteers to this study, both healthy volunteers and patients with known masld. volunteers will attend the unit to undergo all assessments on one day. once consent is given with a study research physician, bloods will be taken and body measurements made (including bmi, weight, waist circumference). a full medical history and physical examination will then be performed by the research physician. bioimpedance body composition analysis will then be performed on an acuniq device. finally ultrasound of the liver and fibroscan will be performed. once all assessments are complete the study volunteer will be discharged from the unit. once all results are finalised, analysis will be performed on all the data to create a clinical score to predict the presence of masld, both with statistical and machine learning methods.

Eligibility criteria:
inclusion criteria: 1. male or female volunteers aged ≥18 to ≤80 years at the date of signing the informed consent. 2. willingness and ability to provide written, personally signed, and dated informed consent, in accordance with the latest ich good clinical practice (gcp) guidelines and applicable regulations. 3. an understanding, ability and willingness to fully comply with project procedures and restrictions. for part b only: 1. with a known history of masld as evidenced either of: 1. gp diagnosis on hcf 2. documented fibroscan or liver us demonstrating masld exclusion criteria: 1. known alcoholic liver disease, history of cirrhosis of any other cause (metabolic, viral hepatitis or other) 2. any other significant previous liver pathology (liver malignancy, portal hypertension, infiltrative liver disease) 3. alcohol consumption \>30 units per week 4. an implanted cardiac devices

Keywords: fatty liver masld
fundus autofluorescence after vitrectomy for epiretinal membrane

Conditions: Epiretinal Membrane

Summary: fundus autofluorescence (faf) at the macula originates from hyperfluorescence from retinal pigment epithelium (rpe) and blockage of hyperfluorescence by macular pigment. investigators evaluate whether presence of faf may correlate to the postoperative visual outcome for epiretinal membrane.

92 eyes with epiretinal membrane were performed vitreous surgery, epiretinal membrane removal and internal limiting membrane (ilm) peeling. presence of hyperfluorescence in faf at the macular area and best-corrected visual acuity (bcva) was evaluated preoperatively and at postoperative 1, 3, and 6 months with ultra-wide angle imaging.

Eligibility criteria:
inclusion criteria: * the inclusion criteria were patients who underwent vitrectomy and internal limiting membrane removal for epiretinal membrane and had followed for more than 6 months. exclusion criteria: * the patients with follow-up less than 6 months.

Keywords: epiretinal membrane
study of the role of hemostasis in perioperative anaphylaxis

Conditions: Hemoptysis; Perioperative Complication; Anaphylaxis

Summary: anaphylaxis is a severe and life-threatening complication during the perioperative period. perioperative anaphylaxis is still associated with a significant mortality despite quick and efficient management using epinephrine, the mainstay of acute treatment. experimental data and few case reports are suggesting that hemostasis, and more precisely platelets, could play a role in anaphylaxis. our main hypothesis is that activation of the hemostatic system contributes to the severity of the reaction


Eligibility criteria:
inclusion criteria: * patient, male or female, adult * in the perioperative period * in whom the diagnosis of anaphylactic shock is suggested * patient is giving his consent to participate in the study exclusion criteria: * subject under legal protection * subject under guardianship or guardianship * anemia less than 7 g /dl at the time of inclusion